CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Sildenafildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01290484
NCT01290484Phase 2Completed
CompareCT.gov

An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

Stanford University·interventional·Posted Feb 7, 2011·Updated Jun 19, 2015

In Brief

A Phase 2 clinical trial evaluating Sildenafil for Lymphangioma. Completed, enrolled 7 participants across 1 site.

Detailed Summary

There is an unsatisfied medical need for a first-line treatment of lymphatic malformations with a good benefit/risk profile. Based on a patient experience in the institution, the investigators plan to verify whether or not the medication sildenafil has a beneficial effect on lymphatic malformations. The investigators plan to do this by treating patients with lymphatic malformations with the medication sildenafil for a 20 week period. This is an investigator initiated study funded by an Innovations in Patient Care grant and a SPARK grant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphangioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2011
Enrollment StartDec 1, 2010
Primary CompletionApr 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.4 years ago

Interventions

Sildenafildrug

Sildenafil oral tablet three times daily